{"transactions":[{"id":1860860,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":112525,"kind":"person","name":"ORTH ANDREW C.","position":1,"cik":"0001860010","reported_name":"ORTH ANDREW C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T19:00:15.000Z","date":"2023-06-09","kind":"exercise","planned":true,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on March 10, 2023 and will terminate on March 31, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $113.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"50,000 options were granted that vest in four equal annual installments beginning on February 28, 2023."}],"balance_after":37500,"derivative":{"exercise_price":63.55,"expiration_date":"2032-02-27","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001860010-23-000004","document":"wk-form4_1686351600.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1860010/000186001023000004/wk-form4_1686351600.xml","form_type":"4"}},{"id":1860859,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":112525,"kind":"person","name":"ORTH ANDREW C.","position":1,"cik":"0001860010","reported_name":"ORTH ANDREW C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-06-09T19:00:15.000Z","date":"2023-06-09","kind":"sale","planned":true,"acquired":false,"shares":333,"price":129.6972,"value":43189.1676,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on March 10, 2023 and will terminate on March 31, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $113.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades ranging from $129.5600 to $129.7400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":100,"source":{"system":"sec-edgar","filing":"0001860010-23-000004","document":"wk-form4_1686351600.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1860010/000186001023000004/wk-form4_1686351600.xml","form_type":"4"}},{"id":1860858,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":112525,"kind":"person","name":"ORTH ANDREW C.","position":1,"cik":"0001860010","reported_name":"ORTH ANDREW C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-06-09T19:00:15.000Z","date":"2023-06-09","kind":"sale","planned":true,"acquired":false,"shares":6906,"price":128.9441,"value":890487.9546,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on March 10, 2023 and will terminate on March 31, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $113.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades ranging from $128.5600 to $129.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":433,"source":{"system":"sec-edgar","filing":"0001860010-23-000004","document":"wk-form4_1686351600.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1860010/000186001023000004/wk-form4_1686351600.xml","form_type":"4"}},{"id":1860857,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":112525,"kind":"person","name":"ORTH ANDREW C.","position":1,"cik":"0001860010","reported_name":"ORTH ANDREW C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-06-09T19:00:15.000Z","date":"2023-06-09","kind":"sale","planned":true,"acquired":false,"shares":5261,"price":128.1045,"value":673957.7745,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on March 10, 2023 and will terminate on March 31, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $113.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $127.5500 to $128.5400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":7339,"source":{"system":"sec-edgar","filing":"0001860010-23-000004","document":"wk-form4_1686351600.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860010/000186001023000004/wk-form4_1686351600.xml","form_type":"4"}},{"id":1860856,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":112525,"kind":"person","name":"ORTH ANDREW C.","position":1,"cik":"0001860010","reported_name":"ORTH ANDREW C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-06-09T19:00:15.000Z","date":"2023-06-09","kind":"exercise","planned":true,"acquired":true,"shares":12500,"price":63.55,"value":794375.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on March 10, 2023 and will terminate on March 31, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $113.00 per share."}],"balance_after":12600,"source":{"system":"sec-edgar","filing":"0001860010-23-000004","document":"wk-form4_1686351600.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860010/000186001023000004/wk-form4_1686351600.xml","form_type":"4"}},{"id":1987455,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":112525,"kind":"person","name":"ORTH ANDREW C.","position":1,"cik":"0001860010","reported_name":"ORTH ANDREW C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Performance Stock Units","published_at":"2023-02-28T18:45:27.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the corporate performance criteria set by the Company's Compensation Committee for this award."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"If any applicable portion of the performance criteria have been achieved, the award shall vest in two equal annual installments (February 28, 2024 and February 28, 2025)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"If the performance criteria are not achieved, the portion of the award which was capable of vesting on that date will expire."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the corporate performance criteria set by the Company's Compensation Committee for this award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the corporate performance criteria set by the Company's Compensation Committee for this award."}],"balance_after":10000,"derivative":{"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001860010-23-000002","document":"wf-form4_167762789935314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1860010/000186001023000002/wf-form4_167762789935314.xml","form_type":"4"}},{"id":1987454,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":112525,"kind":"person","name":"ORTH ANDREW C.","position":1,"cik":"0001860010","reported_name":"ORTH ANDREW C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-28T18:45:27.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in four equal annual installments beginning on February 28, 2024."}],"balance_after":20000,"derivative":{"exercise_price":81.91,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001860010-23-000002","document":"wf-form4_167762789935314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860010/000186001023000002/wf-form4_167762789935314.xml","form_type":"4"}},{"id":2365815,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":112525,"kind":"person","name":"ORTH ANDREW C.","position":1,"cik":"0001860010","reported_name":"ORTH ANDREW C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-01T21:22:58.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in four equal annual installments beginning on February 28, 2023."}],"balance_after":50000,"derivative":{"exercise_price":63.55,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001860010-22-000002","document":"wf-form4_164618775853736.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860010/000186001022000002/wf-form4_164618775853736.xml","form_type":"4"}},{"id":2686985,"issuer":{"id":3500,"kind":"organization","name":"Krystal Biotech, Inc.","symbol":"KRYS"},"owners":[{"id":112525,"kind":"person","name":"ORTH ANDREW C.","position":1,"cik":"0001860010","reported_name":"ORTH ANDREW C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-02T19:19:42.000Z","date":"2021-05-31","kind":"grant","acquired":true,"shares":205000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in four equal annual installments beginning on May 3, 2022."}],"balance_after":205000,"derivative":{"exercise_price":65.24,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":205000},"source":{"system":"sec-edgar","filing":"0000925421-21-000140","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860010/000092542121000140/edgar.xml","form_type":"4"}}]}